More on HIND

- Summary
- Chart
- Profile
- Historical

Data

- Ratings (10.0 Score)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(NQ:HIND)
Delayed: 2.80 -0.11 (3.78%)
Prev. Close $2.91  
Open$2.85 
52 Wk High$ 
52 Wk Low$ 
Day High$2.99 
Day Low$2.74 
P/E N/A  
EPS$ 
Volume31,357 

Friends, Peers and Foes (?): RSLS LICH (more...)

Feb 25, 2026 04:16 PM Form 8-K Vyome Holdings, Inc For: Feb 20
Feb 24, 2026 08:00 AM Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
Feb 13, 2026 06:10 AM Form 8-K Vyome Holdings, Inc For: Feb 13
Feb 11, 2026 07:01 AM Vyome files for orphan drug status for VT-1953 cancer treatment
Feb 11, 2026 07:00 AM Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Feb 2, 2026 07:00 AM Vyome raises $5.29 million to fund phase 3 drug trial
Feb 2, 2026 07:00 AM Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Jan 28, 2026 09:01 AM Form 8-K Vyome Holdings, Inc For: Jan 28
Jan 27, 2026 08:00 AM Vyome receives independent valuation of $1 billion for VT-1953 drug
Jan 27, 2026 08:00 AM Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
View All Articles

Entities mentioned with HIND

View All Entities